What drives the costs of heart failure care in Germany? A health services cost analysis
- 224 Downloads
Heart failure (HF) represents an increasing burden on health-care systems because of the aging population. The aim of this study was to explore its costs of care in Germany from the payer perspective and to identify the main drivers.
Subjects and methods
As part of a trial, primary care physicians (PCPs) enrolled eligible patients and documented actual clinical and 12-month retrospective ambulatory health-care utilisation data related to HF [PCP and cardiologist contacts, and cardiovascular (CV) medication] and provided the doctors’ reports of hospitalisations during 2004 and 2005, enabling the collection and calculation of costs. Furthermore, each hospitalisation was classified according to the cause of admission into HF, CV or other hospitalisation.
Thirty-seven physicians enrolled 168 patients with complete data of 159 patients (95 %). Patients (mean age 68 ± 10 years, 73 % male, 47 % ischaemic aetiology) had ascertained systolic HF (mean ejection fraction 33 ± 7 %) with NYHA class II/III in 53/45 %. Mean (SD; median) annual costs of 96 hospitalisations, CV medication, and 337 cardiologist and 3,037 PCP practice contacts were 3,545 (8,065; 0), 854 (835; 638), 117 (105; 106) and 269 (190; 233) euros, respectively, totalling 4,792 (8249;1341) euros. Fourteen per cent of all patients incurred 50 % of total costs. Twenty-five HF, 49 CV and 22 other hospitalisations incurred 13, 73 and 14 % of hospital care costs, respectively.
These secondary outcome data might indicate a trend that neither HF ambulatory care nor hospitalisation but rather interventional cardiology is the main cost driver. Planning interventions aimed at reduced hospitalisation and costs should include further clarification of the mechanisms of CV hospitalisation and reimbursement.
Key wordsHeart failure Hospitalisation Hospital admission Cost of illness Germany
We thank all study participants and participating PCPs for their additional participation in the cost of care study.
Conflict of interest
The authors declare that they have no conflict of interest.
The parental trial was supported by the Competence Network Heart Failure, funded by the German Ministry of Education and Research (BMBF), grant no. 01GI0205.
- Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10:933–989PubMedCrossRefGoogle Scholar
- Jaarsma T, van der Wal MHL, Lesman-Leegte I et al (2008) Effect of moderate or intensive disease management program on outcome in patients with heart failure: coordinating study evaluating outcomes of advising and counseling in heart failure (COACH). Arch Intern Med 168:316–324PubMedCrossRefGoogle Scholar
- Peters-Klimm F, Muller-Tasch T, Remppis A et al (2008) Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice—results from a cluster-randomized controlled trial of implementation of a clinical practice guideline. J Eval Clin Pract 14:823–829PubMedCrossRefGoogle Scholar
- Taylor S, Bestall J, Cotter S et al. (2005) Clinical service organisation for heart failure. Cochrane Database Syst Rev: CD002752Google Scholar